McCormick & Company, Incorporat (MKC) Stock Price & How to Invest

McCormick & Company was founded in Baltimore in 1889 and is headquartered in Hunt Valley, Maryland, with a fiscal year ending November 30. It runs two segments. Consumer sells branded spices, herbs, seasoning mixes, condiments and sauces through grocery, club and e-commerce channels, and generated ~$3.95 billion of the ~$6.84 billion in fiscal 2025 net sales under names including McCormick, French's, Frank's RedHot, Lawry's, Old Bay, Cholula, Zatarain's, Stubb's, Schwartz, Ducros and Kamis. Flavor Solutions, at ~$2.89 billion, sells seasonings, coatings, branded foodservice products and custom flavor systems business to business, to packaged food manufacturers and to restaurant chains. The economics are those of a shelf-space franchise: spices are a small line on a grocery bill and a large share of the flavor in a dish, which historically gave McCormick more pricing power than most packaged food and gross margins near 40%.

The investment picture in 2026 is dominated by two transactions rather than by the base business. On January 2, 2026 McCormick paid ~$750 million to Grupo Herdez for an additional 25% of McCormick de Mexico, taking ownership to 75% and consolidating a joint venture formed in 1947, which is why reported net sales jumped ~16.7% in the second quarter while organic growth was only ~1.7%. Then on March 31, 2026 McCormick agreed to combine with Unilever's global Foods business, led by Knorr and Hellmann's, in a Reverse Morris Trust valuing Unilever Foods at an enterprise value of ~$44.8 billion against ~$21.0 billion for McCormick. Shares have fallen roughly 28% year to date to ~$49, near the 52-week low of ~$44.82 and well under the ~$72.41 high set in February 2026, on a combination of deal dilution, expected net leverage of ~4.0x at close, soft U.S. consumer volumes and private-label competition in core spices. Third-quarter fiscal 2026 results are scheduled for October 1, 2026.

The core problem is that organic growth is roughly 1% to 3% and Consumer volumes in the Americas have been flat to slightly negative, with commentary from analysts pointing to share loss in U.S. spices to cheaper private-label and store-brand alternatives after several years of aggressive pricing. GLP-1 weight-loss medications are an additional structural question for the whole packaged-food category, since lower calorie intake across a population reduces the volume base even if flavor intensity per meal rises. The Unilever Foods merger carries the largest single set of risks: a shareholder vote that has not yet happened, a UK antitrust review, expected net leverage of ~4.0x or less at close, and the integration of a business far larger than McCormick into a company that has never operated at that scale, with existing McCormick holders diluted to ~35% of the result. Commodity costs, currency and trade policy have all moved margins around in both directions this year, and the ~$28 million tariff refund that helped the second quarter illustrates how much of recent margin expansion is timing rather than trend. Finally, an M&A fairness investigation by plaintiffs' firms was announced in April 2026 in connection with the merger terms, which is routine for a deal of this size but is one more source of delay.

13 analysts publish price targets on MKC, averaging $60.08 against a $49.09 price as of September 2026, or +22.4%. The published targets run from $52.00 to $75.00, a moderate spread, and the ratings split 7 buy, 8 hold, 0 sell. Over the last six months there have been 2 raises and 9 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full MKC forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on McCormick & Company, Incorporat. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. The Unilever Foods combination. Under the March 2026 agreement, Unilever's Foods business separates and merges with McCormick, with Unilever shareholders expected to hold ~55.1% of the combined company, existing McCormick shareholders ~35.0% and Unilever itself ~9.9%, plus a one-time ~$15.7 billion cash payment to Unilever. The most optimistic published target, $75.00, assumes this works close to its best case.

The case against. The core problem is that organic growth is roughly 1% to 3% and Consumer volumes in the Americas have been flat to slightly negative, with commentary from analysts pointing to share loss in U.S. The most pessimistic target, $52.00, is roughly what MKC is worth if this bites instead.

Read the full bull and bear case on MKC, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see McCormick & Company, Incorporat's investor relations page or your broker.

• Revenue (TTM): ~$7.39B
• Net sales (Q2 FY2026, ended May 31, 2026): ~$1.94B
• Adjusted EPS (Q2 FY2026): ~$0.80
• FY2026 adjusted EPS guidance: ~$3.05 to ~$3.13
• Market cap: ~$13.2B
• Dividend yield: ~3.9%

The trailing price to earnings ratio of roughly 8x is misleading rather than a sign of a cheap stock. Trailing twelve-month EPS of ~$6.01 includes a non-cash gain of ~$3.22 per share booked in the first quarter of 2026 when the previously held 50% interest in McCormick de Mexico was remeasured to fair value on consolidation, so the recurring earnings base is the ~$3.05 to ~$3.13 of adjusted EPS guided for fiscal 2026, which puts the shares near ~16x forward earnings at ~$49. Total debt was ~$4.93 billion against ~$331 million of cash and ~$16.48 billion of total assets on May 31, 2026, and third-quarter results due October 1, 2026 carry a consensus of roughly $0.76 of adjusted EPS on about $1.98 billion of sales.

Other names that sit close to MKC: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get MKC exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so MKC sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where MKC fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

McCormick is a slow-growing, high-margin flavor business with a 40-year record of dividend increases, priced today less on this year's numbers than on whether a transformative Unilever Foods combination and a soft U.S. spice category resolve in its favor.

Whether MKC is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is MKC a buy or a sell?, and where the stock could go from here in the MKC stock forecast.

For income investors, whether MKC pays a dividend and how the payout looks is covered in does MKC pay a dividend? And to weigh MKC against a peer, read the full side-by-side comparisons: MKC vs KHC and MKC vs CAG.